XERIS BIOPHARMA HOLDINGS, INC. Interest Income, Other
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Interest Income, Other of $1.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for the quarter ending 2026-06-30 was $1.46M, a 53.48% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for the quarter ending 2026-03-31 was $1.20M, a 2.30% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for the quarter ending 2025-12-31 was $1.46M, a 60.55% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for the quarter ending 2025-09-30 was $1.16M, a 3.26% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for fiscal 2025 was $4.74M, a 10.88% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for fiscal 2024 was $5.32M, a 12.00% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for fiscal 2023 was $4.75M, a 84.29% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. interest income, other for fiscal 2022 was $2.58M, a 723.64% increase from fiscal 2021.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.46M 10-Q · filed 2026-08-06 | $2.66M 10-Q · filed 2026-08-06 | $4.12M derived: sum of 3 quarters · filed 2026-08-06 | $5.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-07 | $2.66M derived: sum of 2 quarters · filed 2026-05-07 | $3.82M derived: sum of 3 quarters · filed 2026-05-07 | $4.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.62M derived: sum of 2 quarters · filed 2026-03-02 | $3.57M derived: sum of 3 quarters · filed 2026-08-06 | $4.74M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.16M 10-Q · filed 2025-11-06 | $2.11M derived: sum of 2 quarters · filed 2026-08-06 | $3.28M 10-Q · filed 2025-11-06 | $4.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $948.00K 10-Q · filed 2026-08-06 | $2.12M 10-Q · filed 2026-08-06 | $3.03M derived: sum of 3 quarters · filed 2026-08-06 | $4.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.18M 10-Q · filed 2026-05-07 | $2.08M derived: sum of 2 quarters · filed 2026-05-07 | $3.28M derived: sum of 3 quarters · filed 2026-05-07 | $4.57M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $910.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.11M derived: sum of 2 quarters · filed 2026-03-02 | $3.40M derived: sum of 3 quarters · filed 2026-03-02 | $5.32M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-06 | $2.49M derived: sum of 2 quarters · filed 2025-11-06 | $4.41M 10-Q · filed 2025-11-06 | $5.52M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $1.29M 10-Q · filed 2025-08-07 | $3.21M 10-Q · filed 2025-08-07 | $4.32M derived: sum of 3 quarters · filed 2026-03-02 | $5.44M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $1.92M 10-Q · filed 2025-05-08 | $3.03M derived: sum of 2 quarters · filed 2026-03-02 | $4.15M derived: sum of 3 quarters · filed 2026-03-02 | $5.37M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.23M derived: sum of 2 quarters · filed 2026-03-02 | $3.45M derived: sum of 3 quarters · filed 2026-03-02 | $4.75M 10-K · filed 2026-03-02 |
| 2023-09-30 | $1.12M 10-Q · filed 2024-11-08 | $2.34M derived: sum of 2 quarters · filed 2024-11-08 | $3.64M 10-Q · filed 2024-11-08 | $5.49M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $1.22M 10-Q · filed 2024-08-08 | $2.52M 10-Q · filed 2024-08-08 | $4.37M derived: sum of 3 quarters · filed 2025-03-06 | $4.84M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-09 | $3.14M derived: sum of 2 quarters · filed 2025-03-06 | $3.62M derived: sum of 3 quarters · filed 2025-03-06 | $3.81M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.31M derived: sum of 2 quarters · filed 2025-03-06 | $2.51M derived: sum of 3 quarters · filed 2025-03-06 | $2.58M 10-K · filed 2025-03-06 |
| 2022-09-30 | $472.00K 10-Q · filed 2023-11-09 | $667.00K derived: sum of 2 quarters · filed 2023-11-09 | $735.00K 10-Q · filed 2023-11-09 | $805.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $195.00K 10-Q · filed 2023-08-08 | $263.00K 10-Q · filed 2023-08-08 | $333.00K derived: sum of 3 quarters · filed 2024-03-06 | $399.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $68.00K 10-Q · filed 2023-05-09 | $138.00K derived: sum of 2 quarters · filed 2024-03-06 | $204.00K derived: sum of 3 quarters · filed 2024-03-06 | $281.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $136.00K derived: sum of 2 quarters · filed 2024-03-06 | $213.00K derived: sum of 3 quarters · filed 2024-03-06 | $313.00K 10-K · filed 2024-03-06 |
| 2021-09-30 | $66.00K 10-Q · filed 2022-11-09 | $143.00K derived: sum of 2 quarters · filed 2022-11-09 | $243.00K 10-Q · filed 2022-11-09 | $2.27M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $77.00K 10-Q · filed 2022-08-10 | $177.00K 10-Q · filed 2022-08-10 | $2.20M derived: sum of 3 quarters · filed 2022-08-10 | $2.43M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-11 | $2.12M derived: sum of 2 quarters · filed 2022-05-11 | $2.35M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $2.25M derived: sum of 2 quarters · filed 2022-03-11 | $2.96M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $232.00K 10-Q · filed 2021-11-10 | $943.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |